Scotch Plains, NJ, United States of America

Hugh Y Zhu

This inventor holds 10 USPTO granted patents and 6 published patent applications and 7 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation, Merck Sharp + Dohme B.v.. Active years: 2008-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hugh Y Zhu. Retrieved from https://idiyas.com/inventor/hugh-y-zhu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 6)

% Patents Active = 60.0

EPO Patents = 7 (Patent Applications = 14)

Average Co-Inventor Count = 11.4

ph-index = 3

Forward Citations = 31(Granted Patents)

Location History:

Scotch Plains, NJ (US) (2008 - 2013)
Kenilworth, NJ (US) (2014)
Warren, NJ (US) (2014 - 2017)

Company Filing History:

6 out of 2,405

Merck Sharp + Dohme Corp.

Merck Sharp + Dohme B.v.

where one patent can have more than one assignee

Years Active: 2008-2017

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9718828 - BTK Inhibitors (2017-08-01),

2. 8999966 - Compounds that are ERK inhibitors (2015-04-07),

3. 8999957 - Heterocyclic compounds as ERK inhibitors (2015-04-07),

4. 8716483 - Compounds that are ERK inhibitors (2014-05-06),

5. 8658651 - Compounds that are ERK inhibitors (2014-02-25),

6. 8546404 - Compounds that are ERK inhibitors (2013-10-01),

7. 7807672 - Compounds that are ERK inhibitors (2010-10-05),

8. 7557107 - Farnesyl protein transferase inhibitors as antitumor agents (2009-07-07),

9. 7425640 - Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents (2008-09-16),

10. 7342016 - Farnesyl protein transferase inhibitors as antitumor agents (2008-03-11),

Title: The Innovative Journey of Hugh Y. Zhu

Introduction

Hugh Y. Zhu, a prominent inventor based in Scotch Plains, NJ, has made significant contributions to the field of pharmaceutical sciences, particularly in the development of innovative compounds aimed at treating various diseases. With a remarkable portfolio of 10 patents to his name, Zhu's work reflects a dedication to advancing medical therapies through innovative chemistry.

Latest Patents

Among his latest innovations are breakthrough patents focused on Bruton's Tyrosine Kinase (BTK) inhibitors and heterocyclic compounds designed as ERK inhibitors. His patent concerning the BTK inhibitors details 6-5 membered fused pyridine ring compounds, highlighting their potential in the treatment of disorders mediated by Bruton's Tyrosine Kinase. Furthermore, his work on heterocyclic compounds outlines a novel compound designed to act as an ERK inhibitor, with pharmaceutical applications in cancer treatment. These compounds demonstrate the versatility and impact of Zhu’s work in the pharmaceutical industry.

Career Highlights

Hugh Y. Zhu has held significant positions at renowned companies including Merck Sharp & Dohme Corporation and Schering Corporation. His extensive experience in these leading organizations has further honed his skills in drug development and patent innovation, enabling him to make substantial contributions to the field of medicine.

Collaborations

Throughout his career, Zhu has collaborated with notable professionals, including Alan B. Cooper and Jagdish A. Desai. These collaborations have likely enriched his research endeavors and led to the successful development of his innovative compounds.

Conclusion

Hugh Y. Zhu's inventive spirit and dedication to pharmaceutical advancements mark him as an influential figure in the field of drug development. His patents not only reflect a commitment to innovation but also hold the potential to make significant impacts on medical therapies. As he continues to progress in his career, his contributions are sure to inspire future advancements in pharmaceutical inventions.

Profile summary based on public USPTO records.